* Administered as a sublingual spray, Sativex is a cannabinoid drug developed by GW Pharmaceuticals which contains a 1:1 ratio of CBD to THC.
* According to its makers, Sativex has been specifically designed to treat spasticity in multiple sclerosis, an incurable neurodegenerative disease affecting the nervous system.
*To date, Sativex has been licensed in 29 countries across the world, emerging as a global pioneer in the field of cannabis-based drugs – it is allowed in countries like Spain and the UK, where medical cannabis remains an illegal substance.
What is Sativex and what is it used for?
Sativex is the trade name for nabiximol, a standardised, clinically tested cannabinoid drug produced from plants of Cannabis sativa L. bred specifically to produce two separate chemotypes, which express their cannabinoid content either as delta-9-tetrahidrocannabinol (THC) or as cannabidiol (CBD). Each 100 microlitre bottle contains 2.7 mg THC and 2.5 mg CBD, as well as up to 0.04 g alcohol.
Sativex modulates the body’s endocannabinoid system, which plays a part in signal transduction in the nervous system. Some diseases including multiple sclerosis can alter the functioning of the endocannabinoid system, which can lead to spasticity and other associated symptoms, but some active ingredients in the cannabis plant including THC and CBD can mimic the activity of the endocannabinoid system, reducing spasticity in multiple sclerosis.
To date, Sativex has been administered to over 1,500 patients in clinical studies, and over 3,500 patients have been monitored for safety in observational studies in the UE. At the global level, Sativex has been prescribed to some 50,000 patients.
A bit of history
Sativex is the result of a wise combination of some of the most unique cannabis plants owned by Robert Connell Clarke a David Watson – aka Sam “The Skunkman – a legendary figure in the history of contemporary cannabis and the creator of some of the most iconic strains of all times, such as Northern Ligths and Skunk.
In the late 90’s, the duo was joined by Dr Geoffrey Guy, who had conducted research on the palliative effects of opioid-based drugs before focusing on cannabinoids. Convinced of their untapped potential, he founded GW Pharmaceuticals in 1998,